📇 Rhumatologue ·

M CHARLES BENHAMOU

Pourquoi vous devez consulter ce praticien

1 raison identifiée

Auteur de référence en rhumatologie
50 articles scientifiques publiés — un praticien à la pointe de la recherche

Rhumatologue

RPPS 10000243609

✨ Génération du profil synthétique IA en cours…

Lieu de consultation

Tarifs & secteur de conventionnement

Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).

📊 Comprendre le remboursement

Prendre rendez-vous & contact

🗓 Trouver sur Doctolib 📇 Ajouter à mes contacts

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2010

📚 315 citations🎯 RCR 10.05Top 3% NIH🩺 Clinique🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

Abstract Patients treated with bisphosphonates for osteoporosis may discontinue or require a switch to other therapies. Denosumab binds to RANKL and is a potent inhibitor of bone resorption that has been shown to increase bone mineral density (BMD) and decrease fracture risk in postmenopausal women with osteoporosis. This was a multicenter, international, randomized, double-blind, double-dummy study in 504 postmenopausal women ≥ 55 years of age with a BMD T-score of −2.0 or less and −4.0 or more who had been receiving alendronate therapy for at least 6 months. Subjects received open-label branded alendronate 70 mg once weekly for 1 month and then were randomly assigned to either continued weekly alendronate therapy or subcutaneous denosumab 60 mg every 6 months and were followed for 12 months. Changes in BMD and biochemical markers of bone turnover were evaluated. In subjects transitioning to denosumab, total hip BMD increased by 1.90% at month 12 compared with a 1.05% increase in subjects continuing on alendronate (p &lt; .0001). Significantly greater BMD gains with denosumab compared with alendronate also were achieved at 12 months at the lumbar spine, femoral neck, and 1/3 radius (all p &lt; .0125). Median serum CTX levels remained near baseline in the alendronate group and were significantly decreased versus alendronate (p &lt; .0001) at all time points with denosumab. Adverse events and serious adverse events were balanced between groups. No clinical hypocalcemic adverse events were reported. Transition to denosumab produced greater increases in BMD at all measured skeletal sites and a greater reduction in bone turnover than did continued alendronate with a similar safety profile in both groups. Copyright © 2010 American Society for Bone and Mineral Research

Alcohol and bone: review of dose effects and mechanisms

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2012

📚 244 citations🎯 RCR 9.68Top 3% NIH

Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2012

📚 118 citations🎯 RCR 4.32Top 10% NIH🩺 Clinique🔓 Open Access📄 PDF gratuit ↗

Lire l'abstract Crossref ↓

Abstract Denosumab reduces the risk of new vertebral and nonvertebral fractures. Previous trials suggest that the efficacy of antiresorptives on fractures might differ by patients' characteristics, such as age, bone mineral density (BMD), and fracture history. In the FREEDOM study, 7808 women aged 60 to 90 years with osteoporosis were randomly assigned to receive subcutaneous injections of denosumab (60 mg) or placebo every 6 months for 3 years. New vertebral and nonvertebral fractures were radiologically confirmed. Subgroup analyses described in this article were prospectively planned before study unblinding to evaluate the effect of denosumab on new vertebral and nonvertebral fractures across various subgroups. Compared with placebo, denosumab decreased the risk of new vertebral fractures in the overall study population over 3 years. This effect did not significantly differ for any of the nine subgroups analyzed (p &gt; 0.09 for all potential interactions). Denosumab also reduced all nonvertebral fractures by 20% in the full study cohort over 3 years. This risk reduction was statistically significant in women with a baseline femoral neck BMD T-score ≤ −2.5 but not in those with a T-score &gt; −2.5; in those with a body mass index (BMI) &lt; 25 kg/m2 but not ≥ 25 kg/m2; and in those without but not with a prevalent vertebral fracture. These differential treatment effects were not explained by differences in BMD responses to denosumab. Denosumab 60 mg administered every 6 months for 3 years in women with osteoporosis reduced the risk of new vertebral fractures to a similar degree in all subgroups. The effect of denosumab on nonvertebral fracture risk differed by femoral neck BMD, BMI, and prevalent vertebral fracture at baseline. © 2012 American Society for Bone and Mineral Research

Cookies & analyse de trafic

M CHARLES BENHAMOU

Pourquoi vous devez consulter ce praticien

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (50) — classées par pathologie

Transversal35

Ostéoporose4

Biothérapies non-anti-TNF2

Pharmacovigilance2

Connectivite mixte1

Essai clinique1

Génétique1

IA en rhumatologie1

Pédiatrie1

Revue générale1

Sjögren1

Vascularites1

Partager cette fiche